The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Eligibility criteria and endpoints in metastatic renal cell carcinoma trials.
 
Sarah Wong
No Relationships to Disclose
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Novartis; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Novartis; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Georg A. Bjarnason
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Scott A. North
Honoraria - Astellas Pharma; Janssen-Ortho; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen Oncology; Merck; Novartis; Pfizer; Roche Canada; Sanofi
 
Srikala S. Sridhar
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Sanofi (Inst)